6 completed, 5 active not recruiting, 5 recruiting, 1 enrolling by invitation. 19 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 6, Active not recruiting 5, Recruiting 5, Enrolling by invitation 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Hairy Cell Leukemia: new trials by email Literature Review of Hairy Cell Leukemia trials Research Report on Hairy Cell Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant Zanubrutinib - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 2 | Enrolling by invitation | Bnai Zion Medical Center | 12 | 2026-06-01 | 2026-07-08 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) Vemurafenib, Obinutuzumab, Cladribine - Hairy Cell Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 86 | 2024-09-09 | 2026-09-09 |
| Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia Low dose vemurafenib plus rituximab - Hairy Cell Leukemia | Phase 2 | Completed | Scripps Health | 15 | 2022-03-02 | 2026-04-24 |
| Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant binimetinib - Hairy Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 40 | 2021-01-07 | 2026-10-16 |
| Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL binimetinib, Encorafenib - Hairy Cell Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 28 | 2020-10-28 | 2026-06-12 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia Vemurafenib, Obinutuzumab - Hairy Cell Leukemia, Leukemia | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2018-02-09 | 2026-08-24 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL | Phase 1 / Phase 2 | Completed | Acerta Pharma BV | 161 | 2015-02-20 | 2026-05-13 |
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 44 | 2013-04-30 | 2026-11-12 |
| BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Vemurafenib - Hairy Cell Leukemia | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 36 | 2012-10-01 | 2025-10-20 |
| Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia Pentostatin, Rituximab, Bendamustine - Hairy Cell Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 69 | 2010-07-01 | 2026-10-15 |
| Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia BL22 (CAT-3888) - Hairy Cell Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2009-02-01 | 2015-10-29 |
| Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia Cladribine, Rituximab, BMbx - Hairy Cell Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 175 | 2008-10-20 | 2026-08-18 |
| LMB-2 to Treat Hairy Cell Leukemia Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin - Hairy Cell Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2006-05-02 | 2023-11-14 |
| Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia Cladribine, Laboratory Biomarker Analysis, Rituximab - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 150 | 2004-06-10 | 2026-06-11 |
| Therapy Optimisation for the Treatment of Hairy Cell Leukemia Cladribine s.c. injection, HCL treatment - Hairy Cell Leukemia | Phase 2 / Phase 3 | Recruiting | University of Giessen | 210 | 2004-05-01 | 2024-08-22 |
| A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia Roferon-A - Hairy Cell Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 56 | 1997-01-01 | 2008-03-04 |
Leukemia, Hairy Cell (19) · Leukemia (3) · Hematologic Neoplasms (2) · Hodgkin Disease (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Neoplasm, Residual (2) · Anemia (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Burkitt Lymphoma (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Prolymphocytic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1)
Hematologic Diseases (19) · Hemic and Lymphatic Diseases (19) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Lymphatic Diseases (19) · Lymphoproliferative Disorders (19) · Neoplasms (19) · Neoplasms by Histologic Type (19) · Leukemia (16) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Chronic Disease (3) · Disease Attributes (3) · Leukemia, Lymphoid (3) · Lymphoma (3)
Rituximab (6) · Cladribine (4) · Vemurafenib (4) · obinutuzumab (3) · Biopsy (2) · CT-P10 (2) · Specimen Handling (2) · binimetinib (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · Acetaminophen (1) · Adrenal Cortex Hormones (1) · B3(Fv)-PE38KDEL recombinant immunotoxin (1) · Bendamustine Hydrochloride (1) · Bronchodilator Agents (1) · Caves (1)
National Cancer Institute (NCI) (9) · Memorial Sloan Kettering Cancer Center (3) · Acerta Pharma BV (1) · Alexey Danilov, MD (1) · Bnai Zion Medical Center (1) · City of Hope Medical Center (1) · M.D. Anderson Cancer Center (1) · Scripps Health (1) · University of Giessen (1)
United States (16) · Germany (1) · Israel (1)
Robert J Kreitman, M.D. (6) · Jae Park, MD (2) · Alan Saven, MD (1) · Craig Okada, M.D. (1) · Farhad Ravandi-Kashani (1) · Ibrahim Aldoss, MD (1) · Jae H. Park, MD (1) · Kerry A Rogers (1) · Mathias J Rummel, Prof. Dr. (1) · Seema A Bhat (1)
PMID 18596230, PMID 21821712, PMID 26352686, PMID 32109194, PMID 33754642, PMID 34196037, PMID 34607348, PMID 35930750, PMID 38320179, PMID 41060318, PMID 42308249
UM1CA186712 (2), N01CM00039 (1), P30CA016058 (1), U01CA076576 (1)